Cardiome news from FierceBiotech
News
Cardiome shares plunge on approvable letter
After riding high on the news of positive data from a recent Phase IIb trial, shares of Cardiome Pharma swiftly sank 30 percent after investors heard that the FDA's "approvable" letter for Kynapid Read more...
Cardiome's CBO discusses changes at FDA
During a conference call with investors yesterday, Cardiome's President and Chief Business Officer, Doug Janzen, had some interesting thoughts on the Read more...
ALSO NOTED: Rumor Mill: AstraZeneca a possible Shire suitor; Cardiome baits hook for partners; Vertex shares keep sliding; and
> Shire is suddenly the talk of the town as investors and investment banks publicly mull a match-up with AstraZeneca. Read more...
ALSO NOTED: Cardiome awaits FDA decision; Congress to investigate Vytorin scandal; and much more...
> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report > It seems that many black U.S. residents Read more...
Astellas inks $537M deal for Agensys
Japan's Astellas has forged a deal to buy Santa Monica, CA-based Read more...
SPOTLIGHT: Cardiome, Astellas get panel date
The FDA as extended its review of a new therapy for abnormal heart rhythm and asked Cardiome and Astellas to sit in on a panel review of the drug. The panel review will be held on December 11 and 12 Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets